Klinične študije za Rak dojke v Kansas
26 študij za Rak dojke išče udeležence na lokacijah v Kansas.
Mesta v Kansas
- Kansas City12 študij
- Overland Park10 študij
- Topeka6 študij
- Wichita5 študij
- Hays4 študij
- Salina4 študij
- Olathe4 študij
Uradno besedilo študije (angleško)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Central Care Cancer Center - Garden City, Garden City
- Central Care Cancer Center - Great Bend, Great Bend
- Veteran Administration Eastern Kansas Healthcare, Leavenworth
- in še 4
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
Starost 40–75 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT05334069The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
- The University of Kansas Cancer Center, Westwood
Vključevanje udeležencevFaza 3
Starost 60 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06377852A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Cancer Center of Kansas, Wichita
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 15. sep. 2026 · NCT06492616Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
- University of Kansas Hospital-Cancer Center, Fairway
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 4. sep. 2026 · NCT07287917Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- University of Kansas Cancer Center, Westwood
- Cancer Center of Kansas, Wichita
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 3. sep. 2026 · NCT06982521Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Central Care Cancer Center - Garden City, Garden City
- Central Care Cancer Center - Great Bend, Great Bend
- HaysMed, Hays
- in še 10
Vključevanje udeležencevFaza 3
Starost 18–60 · Ženske · Posodobljeno 2. sep. 2026 · NCT05879926Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- AMR Kansas City Oncology, Kansas City
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 2. sep. 2026 · NCT06072612Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
- Hays Medical Center Dreiling-Schmidt Cancer Institute, Hays
- KCCC West, Kansas City
- KCCC Overland Park, Overland Park
- in še 3
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
Vse starosti · Vsi spoli · Posodobljeno 18. avg. 2026 · NCT02302742Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
- University of Kansas Cancer Center, Kansas City
- University of Kansas Cancer Center-Overland Park, Overland Park
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 17. avg. 2026 · NCT06500481Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
- University of Kansas Medical Center, Fairway
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 12. avg. 2026 · NCT06263543Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
- University of Kansas Cancer Center, Kansas City
Vključevanje udeležencevFaza 2Vabljeni zdravi prostovoljci
Starost 45–74 · Ženske · Posodobljeno 4. avg. 2026 · NCT06195306Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- University of Kansas Medical Center (KUMC), Westwood
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 4. avg. 2026 · NCT05579366E-Mindfulness Approaches for Living After Breast Cancer
- Cotton O'Neil Cancer Center / Stormont Vail Health, Topeka
Vključevanje udeležencevFaza 3
Starost 18–50 · Vsi spoli · Posodobljeno 4. avg. 2026 · NCT06748222Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
- University of Kansas Cancer Center, Kansas City
Vključevanje udeležencevFaza 2
Starost 18–55 · Ženske · Posodobljeno 27. jul. 2026 · NCT06184750HER2-positive Breast Cancer Registry
- The University of Kansas Cancer Center, Westwood
Vključevanje udeležencevOpazovalna študija
Starost 18 in več · Vsi spoli · Posodobljeno 17. jul. 2026 · NCT06603597Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
- University of Kansas Cancer Center, Kansas City
Vključevanje udeležencevFaza 2
Starost 35 in več · Ženske · Posodobljeno 7. jul. 2026 · NCT05941520Integrated Cancer Repository for Cancer Research
- Saint Luke's Cancer Instititute - South, Overland Park
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
Starost 19–110 · Vsi spoli · Posodobljeno 29. jun. 2026 · NCT02012699Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- The University of Kansas Cancer Center, Westwood
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 18. maj 2026 · NCT06757634Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer
- The University of Kansas Cancer Center (KUCC), Fairway
- The University of Kansas Cancer Center - Westwood, Kansas City
- KUCC - Indian Creek, Overland Park
- in še 3
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 6. maj 2026 · NCT07220135De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- University of Kansas Cancer Center, Kansas City
- The University of Kansas Cancer Center - Olathe, Olathe
- University of Kansas Cancer Center-Overland Park, Overland Park
- in še 8
Vključevanje udeležencevFaza 3
Starost 50–70 · Vsi spoli · Posodobljeno 23. apr. 2026 · NCT04852887Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
- The University of Kansas Cancer Center, Westwood
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 20. apr. 2026 · NCT06374459Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- HaysMed, Hays
- Lawrence Memorial Hospital, Lawrence
- The University of Kansas Cancer Center - Olathe, Olathe
- in še 6
Vključevanje udeležencevOpazovalna študija
Starost 18 in več · Vsi spoli · Posodobljeno 17. mar. 2026 · NCT06418204EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
- University of Kansas Cancer Center, Westwood
Vključevanje udeležencevOpazovalna študija
Starost 18 in več · Vsi spoli · Posodobljeno 20. jan. 2026 · NCT06401421Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
- Cancer Center of Kansas, Wichita
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 10. nov. 2025 · NCT04553770High Risk Breast Clinic: Protocol for Women at Increased Risk for Developing Breast Cancer
- University of Kansas Medical Center, Kansas City
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
Starost 30–65 · Ženske · Posodobljeno 29. okt. 2025 · NCT00291096S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- HaysMed University of Kansas Health System, Hays
- University of Kansas Cancer Center-West, Kansas City
- University of Kansas Cancer Center, Kansas City
- in še 5
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 8. okt. 2025 · NCT03418961Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.